Publications by authors named "Michela Guida"
Introduction: Tuberculosis (TB) remains a major global health issue, causing around 10 million new cases and 1.3 million deaths in 2022. The challenge is compounded by multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains, and co-infection with HIV.
View Article and Find Full Text PDFLipopeptide antibiotics disrupt interactions of undecaprenyl phosphate with UptA.
Proc Natl Acad Sci U S A
October 2024
Article Synopsis
- - The peptidoglycan pathway, crucial for bacterial cell wall formation, targets the translocation of undecaprenyl phosphate (C-P) across the membrane, which is facilitated by proteins like DedA and UptA.
- - Research using native mass spectrometry reveals that UptA binds C-P more effectively than shorter-chain lipid analogs and interacts in a pH-sensitive manner.
- - The study also finds that certain lipopeptide antibiotics can inhibit UptA by competing for its binding site, suggesting potential directions for developing new antibiotics that target lipid recycling processes in bacteria.
Article Synopsis
- - The World Health Organization reported that in 2022, 10.6 million people were diagnosed with tuberculosis (TB) and 1.3 million died, highlighting a growing problem with multi-drug-resistant (MDR) and extensively drug-resistant (XDR) strains of the bacteria.
- - TB bacteria have adapted to survive inside host cells by producing their own amino acids, which means targeting amino acid biosynthesis could help develop new treatments that outsmart the bacteria's defenses.
- - Recent progress in drug discovery shows that inhibitors of tryptophan biosynthesis are promising, suggesting that focusing on optimizing these compounds could enhance the development of effective TB therapies in the future.
Enterovirus B (EV-B)-related diseases, which can be life threatening in high-risk populations, have been recognized as a serious health problem, but their clinical treatment is largely supportive, and no selective antivirals are available on the market. As their clinical relevance has become more serious, efforts in the field of anti-EV-B inhibitors have greatly increased and many potential antivirals with very high selectivity indexes and promising in vitro activities have been discovered. The scope of this review encompasses recent advances in the discovery of new compounds with anti-viral activity against EV-B, as well as further progress in repurposing drugs to treat these infections.
View Article and Find Full Text PDFAims: The aim of this real-world study is to evaluate the effect of glucagon-like peptide1 receptor-agonist (GLP1 RA) and sodium-glucose co-transporter2 inhibitor (SGLT2i) on coronary heart disease (CHD) risk, in patients with type 2 diabetes (T2D) in primary cardiovascular prevention.
Methods: Data from 312 patients with T2D, without CHD history, starting treatment with GLP1 RA (n = 174) or SGLT2i (n = 138), were retrospectively collected. UKPDS-RE score was used to estimate 10-years risk for CHD before and 6, 12 and 24 months after prescription.